137506-94-6

Basic information

• Product Name: (5Z)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one
• CAS NO: 137506-94-6
• Molecular Formula: C₁₈H₂₃NO₂S₂
• Molecular Weight: 349.5107
• Mol File: 137506-94-6.mol
• Article Data: 6

Chemical Properties

• Density: 1.24g/cm³
• Refractive Index: 1.631
• CAS DataBase Reference: (5Z)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: (5Z)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one(137506-94-6)
• EPA Substance Registry System: (5Z)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one(137506-94-6)

Safety Data

• Hazardous Substances Data: 137506-94-6(Hazardous Substances Data)

Usage

Description

(5Z)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one is a thiazolidine derivative with potent antioxidant properties. It features a thioxo-1,3-thiazolidin-4-one core and a 3,5-di-tert-butyl-4-hydroxybenzylidene moiety, which contribute to its ability to scavenge free radicals and protect against oxidative stress.

Uses

Used in Pharmaceutical Applications:
(5Z)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one is used as a pharmaceutical agent for its potential role in the treatment or prevention of diseases related to oxidative damage. Its antioxidant activity may contribute to managing or mitigating the effects of neurodegenerative disorders and cardiovascular diseases.
Used in Cosmetic Applications:
In the cosmetic industry, (5Z)-5-(3,5-di-tert-butyl-4-hydroxybenzylidene)-2-thioxo-1,3-thiazolidin-4-one is used as an ingredient in anti-aging or skin-care products. Its ability to neutralize free radicals can help protect the skin from oxidative stress, potentially reducing the visible signs of aging and promoting skin health.

Upstream product

• 110-89-4 piperidine 
• 141-84-4 2-thioxo-4-thiazolidinone 
• 1620-98-0 3,5-di-t-butyl-4-hydroxybenzaldehyde 

Downstream Products

• 107902-67-0 (-)-5-<<3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl>methyl>-4-thiazolidinone 
• 107902-67-0 (+)-5-<<3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl>methyl>-4-thiazolidinone 
• 107902-67-0 tazofelone 
• 136433-34-6 Tazofelone sulfoxide 
• 139226-40-7 (Z)-5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]methylene]-2-(methylthio)-4(5H)-thiazolone 
• 107902-68-1 5-{[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-methyl}-2-thioxo-4-thiazolidinone 

Relevant articles and documents

Synthesis and anti-inflammatory activity of (3,5-di-tert-butyl-4-hydroxybenzylidene) cyclanones and related compounds

Some (3,5-di-tert-butyl-4-hydroxybenzylidene) cyclanones were synthesized and evaluated for anti-inflammatory activity in carragenin-induced rat paw edema assay. These compounds are slightly less active than phenylbutazone. Their inhibitory effects in vit

Synthesis of enantioenriched 4-thiazolidinone (-)-LY213829 by chemoselective benzylamide cleavage in the presence of a C-S bond

(R)-2-Methylbenzylamine has been used to covalently 'resolve' thiol acid 7 and assemble 4-thiazolidinone 8a in one step. Selective deprotection of the 2-methylbenzylamide using lithium in ammonia/THF has been achieved in the presence of a readily hydrogen

Pyridine derivatives, their production and use

There is disclosed a pharmaceutical composition for providing antiinflammatory, antipyretic, analgesic, antiallergic, immunosuppressing or immunomodulating activity which comprises a pyridine derivative of the formula (I): STR1 wherein R is an optionally substituted pyridine ring, X is a oxygen atom or --S(O)n--, wherein n is 0, 1 or 2, A is a bivalent C1-15 hydrocarbon residue whose branched moiety may have a substituent, Y is an oxygen or sulfur atom, R3 is a hydrogen atom or an optionally substituted hydrocarbon residue, R4 is an optionally substituted hydrocarbon residue or an optionally substituted monocyclic or bicyclic heterocyclic group, R3 and R4 may be joined together with the carbamoyl group or the thiocarbamoyl group to which they are attached to form an optionally substituted heterocyclic group, or R3 or R4 may be independently attached to A to form a ring, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or diluent.